Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression

Streckfus, Charles F.; Arreola, Daniel D.; Edwards, Cynthia; Bigler, Lenora

doi:10.1155/2012/413256

Cited by 30 publications

(35 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This difference in expression can probably be explained by the individual/population profiles; for example, tobacco users were included in the present study, while Streckfus et al (25) excluded tobacco smokers. However, the same group (26,27) found the α-enolase protein upregulated in the saliva pool of IDC cases [histological grade 2, human epidermal growth factor receptor 2 (HER2)-positive or -negative, and positive sentinel lymph nodes]. The present study results for the IDC tumors (luminal A and B) were in agreement with these findings.…”

Section: Discussionsupporting

confidence: 90%

“…The same variability was observed in other studies (25)(26)(27)(28). For example, the α-2-macroglobulin described in the saliva pool of cases with IDC (histological grade 2, HER2-positive or -negative, and positive sentinel lymph nodes) was upregulated (27), while in the saliva pools of the present study (IDC and FBR) α-2-macroglobulin was downregulated.…”

Section: Discussionsupporting

confidence: 88%

“…The present study results on proteins, such as deleted in malignant brain tumors 1 and leukocyte elastase proteins, also showed contradictory levels of expression compared with the studies by Streckfus et al (26,27). According to the studies, these proteins showed underexpression in the pool of saliva from women affected with IDC (histological grade 2, negative HER2 receptors and positive sentinel lymph nodes).…”

Section: Discussioncontrasting

confidence: 68%

“…The proteins present in the saliva and plasma, according to their functional class determined by the PANTHER program version 10.0, revealed immune system proteins, binding to nucleic acids and transportation proteins (data not shown), which are common among tumors (4,(25)(26)(27)(28)(29)(30). When observing the interactome, the highlighted proteins were involved in the initial process of carcinogenesis (data not shown), for example, the metalloproteinases and epidermal growth factor receptor (31).…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Proteomic profile of saliva and plasma from women with impalpable breast lesions

et al. 2016

View full text Add to dashboard Cite

Abstract. The present study evaluated the proteomic profile of saliva and plasma from women with impalpable breast lesions using nano-liquid chromatography-quadrupole-time-of-flight (nLC-Q-TOF) technology. Plasma and saliva from patients with fibroadenoma (n=10), infiltrating ductal carcinoma (n=10) and healthy control groups (n=8) were assessed by combinations of inter/intra-group analyses, revealing significant quantitative and qualitative differences. The major differentially-expressed proteins in the saliva of patients compared with the controls were α2-macroglobulin and ceruloplasmin, but the proteins that met the minimum fold-change and P-value cut-offs were leukocyte elastase inhibitor and α-enolase, and deleted in malignant brain tumors 1. Concerning plasma, α-2-macroglobulin and ceruplasmin were upregulated, while other proteins such as haptoglobin, hemopexin and vitamin D-binding protein were downregulated compared with the control. The changes in immune, molecular transport and signaling pathways were the most representative in the proteomic profile of the saliva and plasma. This is the first study to describe the proteome of saliva and plasma from the same women with impalpable breast lesions.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 88%

Section: Discussioncontrasting

confidence: 68%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Proteomic profile of saliva and plasma from women with impalpable breast lesions

et al. 2016

View full text Add to dashboard Cite

show abstract

“…29,30,31 Já foi possível detectar o marcador human epidermal growth factor receptor 2 (HER2) solúvel em saliva de pacientes de subgrupo de pacientes de câncer de mama. 32,33 Contudo, a aplicação da detecção do HER2 em saliva apresentou uma série de contrapontos e precisa ser mais pesquisada. 34 Fluido aspirado da mama -NAF O epitélio mamário é formado pelas células dos ductos e lóbulos que estão constantemente secretando e absorvendo o NAF.…”

Section: Salivaunclassified

O presente e o futuro dos marcadores circulantes de câncer

Alves

Delmonico

2015

Revista Hospital Universitário Pedro Ernesto

View full text Add to dashboard Cite

Artigo de revisão ResumoPara alguns tipos de câncer, existem marcadores circulantes em uso que não apresentam especificidade e sensibilidade suficientes. Por isso, novas tecnologias e novos conhecimentos estão emergindo com o objetivo de encontrar os marcadores circulantes ideais para cada subtipo de câncer. Recentemente importantes avanços na pesquisa clínica permitiram a identificação de DNA, RNA, proteínas livres no plasma, na saliva, em descarga mamilar e na urina como potenciais e promissores marcadores para o câncer. Outra possível fonte de marcadores circulantes são as vesículas extracelulares, que têm um papel importante na comunicação celular. Em vista das novas descobertas, algumas das quais reunidas nesta revisão de literatura, os conceitos tradicionais de metástase e de micrometástase merecem ser revistos.Descritores: Metástase neoplásica; Diagnóstico; Plasma; Mama; Saliva; Urina. Abstract The present and the future of circulating cancer markersFor some types of cancer, there are circulating markers in use that don't have sufficient specificity and sensitivity. New technologies and new knowledge are thus emerging in order to find the ideal circulating markers for each cancer subtype. Important recent advances in clinical research have allowed for the identification of free circulating DNA, RNA, and proteins from plasma, saliva, nipple aspirate fluid, and urine as potential and promising circulating markers of cancer. Another possible source of circulating markers are the extracellular vesicles, which play an important role in cell communication. Considering new discoveries, some of which are presented in this review, the traditional models of metastasis and micrometastasis deserve to be reviewed.Keywords: Neoplasm metastasis; Diagnosis; Plasma; Saliva; Breast; Urine. O presente e o futuro dos marcadores circulantes de câncer Resumen El presente y el futuro de los marcadores circulantes de cáncerPara algunos tipos de cáncer, hay marcadores circulantes en uso que tienen especificidad y sensibilidad insuficiente. Por lo tanto, las nuevas tecnologías y los nuevos conocimientos surgen con el fin de encontrar los marcadores circulantes ideales para cada subtipo de cáncer. Recientemente, los avances significativos en la investigación clínica llevaron a la identificatión de DNA, RNA y proteínas libres circulantes en plasma, saliva, secreción del pezón, y orina como posibles y prometedores marcadores de cáncer. Otra posible fuente de marcadores circulantes son las vesículas extracelulares, que desempeñan un papel importante en la comunicación celular. Teniendo en cuenta los nuevos descubrimientos, algunos de los que se ajuntan a esta revisión de la literatura; los modelos tradicionales de metástasis y micrometástasis merecen ser revisados.

show abstract

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

et al. 2016

View full text Add to dashboard Cite

Globally, breast cancer is the second most common cancer among women. Although biomarker discoveries through various proteomic approaches of tissue and serum samples have been studied in breast cancer, urinary proteome alterations in breast cancer are least studied. Urine being a noninvasive biofluid and a significant source of proteins, it has the potential in early diagnosis of breast cancer. This study used complementary quantitative gel-based and gel-free proteomic approaches to find a panel of urinary protein markers that could discriminate HER2 enriched (HE) subtype breast cancer from the healthy controls. A total of 183 differentially expressed proteins were identified using three complementary approaches, namely 2D-DIGE, iTRAQ, and sequential window acquisition of all theoretical mass spectra. The differentially expressed proteins were subjected to various bioinformatics analyses for deciphering the biological context of these proteins using protein analysis through evolutionary relationships, database for annotation, visualization and integrated discovery, and STRING. Multivariate statistical analysis was undertaken to identify the set of most significant proteins, which could discriminate HE breast cancer from healthy controls. Immunoblotting and MRM-based validation in a separate cohort testified a panel of 21 proteins such as zinc-alpha2-glycoprotein, A2GL, retinol-binding protein 4, annexin A1, SAP3, SRC8, gelsolin, kininogen 1, CO9, clusterin, ceruloplasmin, and α1-antitrypsin could be a panel of candidate markers that could discriminate HE breast cancer from healthy controls.

show abstract

Salivary Protein Profiles among HER2/neu-Receptor-Positive and -Negative Breast Cancer Patients: Support for Using Salivary Protein Profiles for Modeling Breast Cancer Progression

Cited by 30 publications

References 17 publications

Proteomic profile of saliva and plasma from women with impalpable breast lesions

Proteomic profile of saliva and plasma from women with impalpable breast lesions

O presente e o futuro dos marcadores circulantes de câncer

Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics

Contact Info

Product

Resources

About